Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

The Original Article was published on 31 August 2016

Nature 537, 50–56 (2016); doi:10.1038/nature19323

Figure 1 of our original Article illustrated that treatment with aducanumab reduced human brain amyloid-β plaques in a dose-dependent fashion as measured by florbetapir positron emission tomography (PET) imaging. The figure gave the visual appearance of standard uptake value ratio (SUVR) reduction in subcortical white matter as well as cortical regions, although statistically validated evidence of dose-dependent SUVR reduction was demonstrated only in cortical regions. We provide an updated figure (Fig. 1 of this Addendum), which includes colour bars and difference images to aid in the understanding and interpretation of the representative florbetapir PET images. An additional panel on the right illustrates the differences between baseline and week 54 images, computed by simple subtraction of the baseline from follow-up images, after co-registration to a common coordinate system. The difference images show that the SUVR reduction (which is unitless) occurs primarily in the cortical regions (highlighted in red) in patients treated with aducanumab.

Figure 1
figure1

This is the updated Fig. 1 of the original Article.

Authors

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sevigny, J., Chiao, P., Bussière, T. et al. Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 546, 564 (2017). https://doi.org/10.1038/nature22809

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing